- Acquired by Amryt Pharma Group, Aug 2021
- Raised $70M funding round, Feb 2015
- Raised $33.5M funding round, Dec 2014
About
Chiasma is a clinical late-stage biopharmaceutical company focused on improving the lives of patients with rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop and ultimately commercialize oral medications that are currently available only as injections. Chiasma is evaluating proteins, peptides, and small molecule drugs that are currently available only by injection but which could potentially be converted to oral delivery using the companys TPE technology. In June 2020, the company received FDA approval for its MYCAPSSA (octreotide) capsules for long-term maintenance treatment in patients with acromegaly. MYCAPPSA is a treatment for chronic acromegaly that can be taken orally in pill form rather than by injection. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. In August 2021, Chiasma was acquired by Amryt , a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
Funding history · 8 rounds · $293.7M total
Q&A
- What is Chiasma's primary focus?
- Chiasma is a clinical late-stage biopharmaceutical company focused on improving the lives of patients with rare and debilitating diseases by developing oral medications that are currently available only as injections, utilizing its Transient Permeability Enhancer (TPE) technology platform.
- When was Chiasma acquired and by whom?
- Chiasma was acquired by Amryt Pharma Group in August 2021.
- What significant product approval did Chiasma receive in 2020?
- In June 2020, Chiasma received FDA approval for its MYCAPSSA (octreotide) capsules for long-term maintenance treatment in patients with acromegaly, offering an oral alternative to injections.
- What is Chiasma's total funding raised?
- Chiasma raised a total of $293,700,000 across multiple funding rounds.
- Which investors participated in Chiasma's February 2015 funding round?
- The February 2015 funding round included investments from MPM Capital.
- What is the employee count for Chiasma?
- Chiasma has an employee count in the 11-50 range.
- Where is Chiasma headquartered?
- Chiasma's headquarters is located in Ness Ziona, Israel.
- What is Chiasma's status as of its acquisition?
- Chiasma is currently in an acquired (inactive) status, following its acquisition by Amryt Pharma Group.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/719282 |
Identifiers & details
| Founded | 2001-4 |
|---|---|
| Employees (exact) | 19 |
| Offices | Needham |
| Status reason | Acquired (Inactive) by Amryt Pharma Group on Aug 2021 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Amryt Pharma Group 2021-08
Radar intelligence
Patents
| EPO | 17 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
GitHub
| Top repos | roots, dredd, travis-ci |
|---|